FDA clears Digirad SPECT/VCT system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Digirad, a provider of medical diagnostic imaging products and personnel and equipment leasing services, has received 510(k) clearance from the FDA, allowing the company to market and manufacture its Cardius X-ACT imaging system.

The Poway, Calif.-based company said its Cardius X-ACT is a rapid cardiac SPECT/VCT imaging system that features a volume-CT (VCT) attenuation correction system that reduces artifacts caused by overlying tissues increasing interpretive ease and accuracy. The X-ACT approach takes advantage of the 24-inch wide detector array. The system's high-speed triple-head design combined with nSPEED software allows the combined cardiac SPECT emission and transmission acquisitions.